ClinicalTrials.gg
CompletedNCT01801436Updated May 16, 2013Results posted

A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma

A Phase 3 interventional study of Bortezomib in Multiple Myeloma, sponsored by Johnson & Johnson Taiwan Ltd. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-05-16.

Sponsored by Johnson & Johnson Taiwan Ltd (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Enrollment
218th of 267
14 · median 41
Started
2006
with 28 others
Phase 3
42 of 271
1 open now
Registered
183rd of 271
by date

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 218th largest by enrollment of the 267 interventional ones that give a count, is one of 29 that started in 2006, is one of 42 in phase 3, and was the 183rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this post marketing study is to determine the plasma concentration of bortezomib (unchanged drug) to assess the pharmacokinetic (PK - the study of the way a drug enters and leaves the blood and tissues over time) properties in the Taiwanese population. It will also provide expanded access (expanded access, sometimes called "compassionate use," is the use of an investigational drug outside of a clinical trial to treat a participant with a serious or immediately life-threatening disease or condition who has no comparable or satisfactory alternative treatment options) to bortezomib for the same group of participants with multiple myeloma (cancer of the types of cells normally found in bone marrow).

Read the detailed description

This is an open-label (all people know the identity of the intervention), single-arm, multi-center (conducted in more than 1 center) study to assess the PK of bortezomib and to provide expanded access to bortezomib for 14 Taiwanese participants with multiple myeloma who have received at least 2 previous lines of therapy (medicine or medical care given to a participant for a disease or condition) and are refractory (not responding to treatment) to or have relapsed (the return of a medical problem) after their last therapy. Eligible participants will receive bortezomib 1.3 milligram (mg) per meter square (m\^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles. Blood samples for PK assessment will be collected on specified time points of Day 1, Day 8, and Day 11 of Cycle 1. Efficacy of the participants will primarily be evaluated by recording 'response to treatment' and 'Karnofsky Performance Status'. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Bortezomib
  • Velcade
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants previously diagnosed with multiple myeloma based on standard criteria
  • Participant has received at least 2 for multiple myeloma and, in the Investigator's opinion, currently requires therapy because of (the return of a medical problem) or progressive disease
  • Female participants either or surgically sterilized or willing to use an acceptable method of from Screening through the Final Visit
  • If male, the participant agrees to use an acceptable barrier method for contraception from Screening through the Final Visit
  • Participant has a performance status classifies participants as to their functional impairment and is used to compare effectiveness of different therapies and to assess the prognosis [outlook, probable outcomes] in individual participants) greater than 60

Exclusion criteria

Exclusion Criteria:

  • If the participant received bortezomib in a previous trial, the Participants' best response to bortezomib must be progressive disease
  • If the participant received bortezomib in a previous trial, the participant must have experienced 1 or more serious adverse events
  • Participants who have received nitrosoureas within 6 weeks or any other chemotherapy (treatment of disease, usually cancer, by chemical agents) within 3 weeks before enrollment
  • Participants who have received (greater than 10 milligram per day prednisone or equivalent) within 3 weeks before enrollment
  • (HIV - a life-threatening infection which you can get from an infected person's blood or from having sex with an infected person)-positive or hepatitis-B surface antigen-positive participants or participants with known active hepatitis-C infection
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Bortezomib

    Bortezomib 1.3 milligram (mg) per meter square (m\^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.

    Drug: Bortezomib

Interventions

  • Bortezomib 1.3 mg per (m\^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.

    Also known as: VELCADE

06

What researchers measure

Primary outcomes

  1. Number of Participants With Response to Treatment at Day 1 of Cycle 5

    Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.

    Time frame: Day 1 of Cycle 5

  2. Number of Participants With Response to Treatment at Day 1 of Cycle 7

    Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.

    Time frame: Day 1 of Cycle 7

  3. Number of Participants With Response to Treatment at Day 11 of Cycle 8

    Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.

    Time frame: Day 11 of Cycle 8

  4. Number of Participants With Karnofsky Performance Status (KPS) Score at Baseline

    The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.

    Time frame: Baseline

  5. Number of Participants With KPS Score at Day 1 of Cycle 1

    The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.

    Time frame: Day 1 of Cycle 1

  6. Number of Participants With KPS Score at Day 1 of Cycle 3

    The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.

    Time frame: Day 1 of Cycle 3

  7. Number of Participants With KPS Score at Day 1 of Cycle 5

    The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.

    Time frame: Day 1 of Cycle 5

  8. Number of Participants With KPS Score at Day 1 of Cycle 7

    The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.

    Time frame: Day 1 of Cycle 7

  9. Number of Participants With KPS Score at Day 11 of Cycle 8

    The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.

    Time frame: Day 11 of Cycle 8

  10. Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 1 of Cycle 1

    The Cmax is observed maximum plasma concentration, taken directly from the plasma concentration-time profile.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1

  11. Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 11 of Cycle 1

    The Cmax is observed maximum plasma concentration, taken directly from the plasma concentration-time profile.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1

  12. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 1 of Cycle 1

    Tmax is the time when Cmax is observed, taken directly from the plasma concentration-time profile.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1

  13. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 11 of Cycle 1

    Tmax is the time when Cmax is observed, taken directly from the plasma concentration-time profile.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1

  14. Elimination Half-Life Period (T1/2) of Bortezomib on Day 1 of Cycle 1

    The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda\[z\]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1

  15. Elimination Half-Life Period (T1/2) of Bortezomib on Day 11 of Cycle 1

    The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda\[z\]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1

  16. Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 1 of Cycle 1

    Lambda(z) is defined as terminal rate-constant which reflect the speed of drug elimination in vivo (within the living), and is estimated by log-linear regression analysis of the terminal phase of the plasma concentration versus time curve for at least 3 points.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1

  17. Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 11 of Cycle 1

    Lambda(z) is defined as terminal rate-constant which reflect the speed of drug elimination in vivo (within the living), and is estimated by log-linear regression analysis of the terminal phase of the plasma concentration versus time curve for at least 3 points.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1

  18. Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 1 of Cycle 1

    The AUC(0-t) is area under the plasma concentration-time curve from time zero to the last quantifiable concentration determined by the trapezoidal rule.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1

  19. Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 11 of Cycle 1

    The AUC(0-t) is area under the plasma concentration-time curve from zero to the last quantifiable concentration determined by the trapezoidal rule.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1

  20. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 1 of Cycle 1

    The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.

    Time frame: Day 1 of Cycle 1

  21. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 11 of Cycle 1

    The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1

  22. Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 1 of Cycle 1

    AUMC is defined as the area under first moment plasma concentration-time curve from time of dosing up to definite time t, to infinity, or to the time of last measurable concentration determined by the following equation: AUMC(0 to infinity)=Cntn/k elimination(el) + Cn/k(el\^2) summation\[(tn - tn\^-1) (Cn\^-1) (tn\^-1)\] + Cntn/2 where Cn=last quantifiable concentration, tn=time at which Cn is measured, k=rate constant.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1

  23. Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 11 of Cycle 1

    AUMC is defined as the area under first moment plasma concentration-time curve from time of dosing up to definite time t, to infinity, or to the time of last measurable concentration determined by the following equation: AUMC(0 to infinity)=Cntn/k elimination(el) + Cn/k(el\^2) summation\[(tn - tn\^-1) (Cn\^-1) (tn\^-1)\] + Cntn/2 where Cn=last quantifiable concentration, tn=time at which Cn is measured, k=rate constant.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1

  24. Mean Residence Time (MRT) of Bortezomib in the Body on Day 1 of Cycle 1

    The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1

  25. Mean Residence Time (MRT) of Bortezomib in the Body on Day 11 of Cycle 1

    The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1

  26. Systemic Clearance (CL) of Bortezomib on Day 1 of Cycle 1

    Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1

  27. Systemic Clearance (CL) of Bortezomib on Day 11 of Cycle 1

    Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1

  28. Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 1 of Cycle 1

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by (D/AUC\[0-infinity\])\*(AUMC\[0-infinity\])/AUC\[0-infinity\]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1

  29. Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 11 of Cycle 1

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by (D/AUC\[0-infinity\])\*(AUMC\[0-infinity\])/AUC\[0-infinity\]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time.

    Time frame: 0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1

07

Results

Posted May 16, 2013

Participant flow

Participant flow — Overall Study
MilestoneBortezomib
Started14
Completed5
Not completed9
Withdrew: Withdrawal by subject3
Withdrew: Adverse event2
Withdrew: Progressive disease4

Outcome measures

PrimaryNumber of Participants With Response to Treatment at Day 1 of Cycle 5

Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.

Time frame:
Day 1 of Cycle 5
Reported as:
Number · Participants
Number of Participants With Response to Treatment at Day 1 of Cycle 5
ParticipantsBortezomib
Complete response1
Response2
Partial Response2
Stable disease1
Progression1
PrimaryNumber of Participants With Response to Treatment at Day 1 of Cycle 7

Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.

Time frame:
Day 1 of Cycle 7
Reported as:
Number · Participants
Number of Participants With Response to Treatment at Day 1 of Cycle 7
ParticipantsBortezomib
Response1
Partial Response3
Stable disease1
PrimaryNumber of Participants With Response to Treatment at Day 11 of Cycle 8

Response to treatment was based on the changes in monoclonal protein (M-protein) in serum and urine. Response categories were complete response: complete clearance of M-protein for at least 6 weeks, response: at least 75 percent reduction in M-protein for at least 2 determinations 6 weeks apart, partial response: 50 to 74 percent reduction in M-protein, minimal response: 25 to 49 percent reduction in M-protein, stable disease: not qualifying minimal response or progression and progression: increased M-protein level in serum or urine or clinical signs of disease progression.

Time frame:
Day 11 of Cycle 8
Reported as:
Number · Participants
Number of Participants With Response to Treatment at Day 11 of Cycle 8
ParticipantsBortezomib
Response2
Partial response3
Minimal response2
Stable disease1
Progression6
PrimaryNumber of Participants With Karnofsky Performance Status (KPS) Score at Baseline

The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.

Time frame:
Baseline
Reported as:
Number · Participants
Number of Participants With Karnofsky Performance Status (KPS) Score at Baseline
ParticipantsBortezomib
KPS Score = 702
KPS Score = 803
KPS Score = 907
KPS Score = 1002
PrimaryNumber of Participants With KPS Score at Day 1 of Cycle 1

The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.

Time frame:
Day 1 of Cycle 1
Reported as:
Number · Participants
Number of Participants With KPS Score at Day 1 of Cycle 1
ParticipantsBortezomib
KPS Score = 702
KPS Score = 805
KPS Score = 905
KPS Score = 1002
PrimaryNumber of Participants With KPS Score at Day 1 of Cycle 3

The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.

Time frame:
Day 1 of Cycle 3
Reported as:
Number · Participants
Number of Participants With KPS Score at Day 1 of Cycle 3
ParticipantsBortezomib
KPS Score = 601
KPS Score = 701
KPS Score = 806
KPS Score = 902
KPS Score = 1002
PrimaryNumber of Participants With KPS Score at Day 1 of Cycle 5

The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.

Time frame:
Day 1 of Cycle 5
Reported as:
Number · Participants
Number of Participants With KPS Score at Day 1 of Cycle 5
ParticipantsBortezomib
KPS Score = 601
KPS Score = 701
KPS Score = 804
KPS Score = 1001
PrimaryNumber of Participants With KPS Score at Day 1 of Cycle 7

The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.

Time frame:
Day 1 of Cycle 7
Reported as:
Number · Participants
Number of Participants With KPS Score at Day 1 of Cycle 7
ParticipantsBortezomib
KPS Score = 601
KPS Score = 802
KPS Score = 901
KPS Score = 1001
PrimaryNumber of Participants With KPS Score at Day 11 of Cycle 8

The KPS Index allows participants to be classified as per their functional impairment (abnormal function). This can be used to compare effectiveness of different therapies (medicine or medical care given to a participant for a disease or condition) and to assess the prognosis (outlook, probable outcomes) in individual participants. KPS was recorded on an 11-point scale (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100.) where '0=Dead' and '100=Normal, no complaints, no evidence of disease'. The lower the Karnofsky score, the worse the survival for most serious illnesses.

Time frame:
Day 11 of Cycle 8
Reported as:
Number · Participants
Number of Participants With KPS Score at Day 11 of Cycle 8
ParticipantsBortezomib
KPS Score = 502
KPS Score = 604
KPS Score = 701
KPS Score = 803
KPS Score = 902
KPS Score = 1002
PrimaryMaximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 1 of Cycle 1

The Cmax is observed maximum plasma concentration, taken directly from the plasma concentration-time profile.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1
Reported as:
Mean · Nanogram per millileter (ng per ml)
Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 1 of Cycle 1
Nanogram per millileter (ng per ml)Bortezomib
Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 1 of Cycle 176.43 ± 38.47
PrimaryMaximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 11 of Cycle 1

The Cmax is observed maximum plasma concentration, taken directly from the plasma concentration-time profile.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1
Reported as:
Mean · ng per ml
Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 11 of Cycle 1
ng per mlBortezomib
Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 11 of Cycle 1127.02 ± 59.80
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 1 of Cycle 1

Tmax is the time when Cmax is observed, taken directly from the plasma concentration-time profile.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1
Reported as:
Mean · Hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 1 of Cycle 1
HoursBortezomib
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 1 of Cycle 10.08 ± 0.00
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 11 of Cycle 1

Tmax is the time when Cmax is observed, taken directly from the plasma concentration-time profile.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1
Reported as:
Mean · Hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 11 of Cycle 1
HoursBortezomib
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 11 of Cycle 10.08 ± 0.01
PrimaryElimination Half-Life Period (T1/2) of Bortezomib on Day 1 of Cycle 1

The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda\[z\]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1
Reported as:
Mean · Hours
Elimination Half-Life Period (T1/2) of Bortezomib on Day 1 of Cycle 1
HoursBortezomib
Elimination Half-Life Period (T1/2) of Bortezomib on Day 1 of Cycle 10.08 ± 0.07
PrimaryElimination Half-Life Period (T1/2) of Bortezomib on Day 11 of Cycle 1

The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda\[z\]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1
Reported as:
Mean · Hours
Elimination Half-Life Period (T1/2) of Bortezomib on Day 11 of Cycle 1
HoursBortezomib
Elimination Half-Life Period (T1/2) of Bortezomib on Day 11 of Cycle 151.55 ± 87.20
PrimaryTerminal Rate Constant (Lambda[z]) of Bortezomib on Day 1 of Cycle 1

Lambda(z) is defined as terminal rate-constant which reflect the speed of drug elimination in vivo (within the living), and is estimated by log-linear regression analysis of the terminal phase of the plasma concentration versus time curve for at least 3 points.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1
Reported as:
Mean · Per Hour
Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 1 of Cycle 1
Per HourBortezomib
Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 1 of Cycle 10.08 ± 0.07
PrimaryTerminal Rate Constant (Lambda[z]) of Bortezomib on Day 11 of Cycle 1

Lambda(z) is defined as terminal rate-constant which reflect the speed of drug elimination in vivo (within the living), and is estimated by log-linear regression analysis of the terminal phase of the plasma concentration versus time curve for at least 3 points.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1
Reported as:
Mean · Per Hour
Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 11 of Cycle 1
Per HourBortezomib
Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 11 of Cycle 10.01 ± 0.01
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 1 of Cycle 1

The AUC(0-t) is area under the plasma concentration-time curve from time zero to the last quantifiable concentration determined by the trapezoidal rule.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1
Reported as:
Mean · Hour*ng per ml
Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 1 of Cycle 1
Hour*ng per mlBortezomib
Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 1 of Cycle 151.86 ± 30.56
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 11 of Cycle 1

The AUC(0-t) is area under the plasma concentration-time curve from zero to the last quantifiable concentration determined by the trapezoidal rule.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1
Reported as:
Mean · Hour*ng per mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 11 of Cycle 1
Hour*ng per mLBortezomib
Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 11 of Cycle 1190.39 ± 55.27
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 1 of Cycle 1

The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.

Time frame:
Day 1 of Cycle 1
Reported as:
Mean · Hour*ng per ml
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 1 of Cycle 1
Hour*ng per mlBortezomib
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 1 of Cycle 1106.99 ± 126.91
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 11 of Cycle 1

The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z), in which C(last) is the last observed quantifiable concentration.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1
Reported as:
Mean · Hour*ng per ml
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 11 of Cycle 1
Hour*ng per mlBortezomib
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 11 of Cycle 1349.62 ± 178.81
PrimaryArea Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 1 of Cycle 1

AUMC is defined as the area under first moment plasma concentration-time curve from time of dosing up to definite time t, to infinity, or to the time of last measurable concentration determined by the following equation: AUMC(0 to infinity)=Cntn/k elimination(el) + Cn/k(el\^2) summation\[(tn - tn\^-1) (Cn\^-1) (tn\^-1)\] + Cntn/2 where Cn=last quantifiable concentration, tn=time at which Cn is measured, k=rate constant.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1
Reported as:
Mean · Hour square*ng per ml
Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 1 of Cycle 1
Hour square*ng per mlBortezomib
Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 1 of Cycle 120678.41 ± 54596.1
PrimaryArea Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 11 of Cycle 1

AUMC is defined as the area under first moment plasma concentration-time curve from time of dosing up to definite time t, to infinity, or to the time of last measurable concentration determined by the following equation: AUMC(0 to infinity)=Cntn/k elimination(el) + Cn/k(el\^2) summation\[(tn - tn\^-1) (Cn\^-1) (tn\^-1)\] + Cntn/2 where Cn=last quantifiable concentration, tn=time at which Cn is measured, k=rate constant.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1
Reported as:
Mean · Hour square*ng per ml
Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 11 of Cycle 1
Hour square*ng per mlBortezomib
Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 11 of Cycle 139414.06 ± 51021.07
PrimaryMean Residence Time (MRT) of Bortezomib in the Body on Day 1 of Cycle 1

The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1
Reported as:
Mean · Hour
Mean Residence Time (MRT) of Bortezomib in the Body on Day 1 of Cycle 1
HourBortezomib
Mean Residence Time (MRT) of Bortezomib in the Body on Day 1 of Cycle 165.97 ± 121.65
PrimaryMean Residence Time (MRT) of Bortezomib in the Body on Day 11 of Cycle 1

The MRT is the average time at which the number of absorbed molecules reside in the body, after single-dose administration, and calculated as AUMC(infinity)/AUC(infinity) where AUMC(infinity) is area under the plasma concentration-time first moment curve from time zero to infinite time and AUC(infinity) is the area under the plasma concentration-time curve from time zero to infinite time.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1
Reported as:
Mean · Hour
Mean Residence Time (MRT) of Bortezomib in the Body on Day 11 of Cycle 1
HourBortezomib
Mean Residence Time (MRT) of Bortezomib in the Body on Day 11 of Cycle 188.74 ± 58.38
PrimarySystemic Clearance (CL) of Bortezomib on Day 1 of Cycle 1

Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1
Reported as:
Mean · Liter per Hour
Systemic Clearance (CL) of Bortezomib on Day 1 of Cycle 1
Liter per HourBortezomib
Systemic Clearance (CL) of Bortezomib on Day 1 of Cycle 125.99 ± 18.54
PrimarySystemic Clearance (CL) of Bortezomib on Day 11 of Cycle 1

Systemic CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1
Reported as:
Mean · Liter per Hour
Systemic Clearance (CL) of Bortezomib on Day 11 of Cycle 1
Liter per HourBortezomib
Systemic Clearance (CL) of Bortezomib on Day 11 of Cycle 14.68 ± 2.46
PrimaryVolume of Distribution at Steady-State (Vss) of Bortezomib on Day 1 of Cycle 1

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by (D/AUC\[0-infinity\])\*(AUMC\[0-infinity\])/AUC\[0-infinity\]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1
Reported as:
Mean · Liter
Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 1 of Cycle 1
LiterBortezomib
Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 1 of Cycle 1483.71 ± 403.04
PrimaryVolume of Distribution at Steady-State (Vss) of Bortezomib on Day 11 of Cycle 1

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state which is estimated by (D/AUC\[0-infinity\])\*(AUMC\[0-infinity\])/AUC\[0-infinity\]) where D is the dose of study drug, AUMC(0-infinity) is the area under the first moment curve extrapolated to infinity and AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time.

Time frame:
0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1
Reported as:
Mean · Liter
Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 11 of Cycle 1
LiterBortezomib
Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 11 of Cycle 1331.68 ± 85.81

Adverse events

Collected over Basleine up to Day 11 of Cycle 8. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bortezomib—14/14 (100%)14/14 (100%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventBortezomib
PneumoniaInfections and infestations4/14
Platelet count decreasedInvestigations4/14
Blood potassium decreasedInvestigations2/14
Blood sodium increasedInvestigations2/14
PancytopeniaBlood and lymphatic system disorders1/14
GastritisGastrointestinal disorders1/14
Mouth ulcerationGastrointestinal disorders1/14
NauseaGastrointestinal disorders1/14
SepsisInfections and infestations1/14
Urinary tract infectionInfections and infestations1/14
Most frequent other events
Showing 10 of 88
Most frequent other events
EventBortezomib
Neutrophil count decreasedInvestigations11/14
White blood cell count decreasedInvestigations11/14
Platelet count decreasedInvestigations10/14
Haemoglobin decreasedInvestigations9/14
DiarrhoeaGastrointestinal disorders8/14
ConstipationGastrointestinal disorders7/14
PyrexiaGeneral disorders7/14
Aspartate aminotransferase increasedInvestigations7/14
NeuralgiaNervous system disorders7/14
AnorexiaMetabolism and nutrition disorders6/14

Baseline characteristics

Age Continuous
Age Continuous(Years)Bortezomib
Mean62.63 ± 8.31
Sex: Female, Male
Sex: Female, Male(Participants)Bortezomib
Female8
Male6
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2013
First posted
Feb 28, 2013
Start
Dec 2006
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
May 16, 2013
Last update
May 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01801436
Responsible party
Sponsor
First posted
Feb 28, 2013
Start date
Dec 2006
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
May 16, 2013
Last update
May 16, 2013

Study contacts

Johnson & Johnson Taiwan Ltd Clinical Trial
study director · Johnson & Johnson Taiwan Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion